{
    "nctId": "NCT01889238",
    "briefTitle": "Safety and Efficacy Study of Enzalutamide in Patients With Advanced, Androgen Receptor-Positive, Triple Negative Breast Cancer",
    "officialTitle": "A PHASE 2, SINGLE-ARM, OPEN-LABEL, MULTICENTER STUDY OF THE CLINICAL ACTIVITY AND SAFETY OF ENZALUTAMIDE IN PATIENTS WITH ADVANCED, ANDROGEN RECEPTOR-POSITIVE, TRIPLE-NEGATIVE BREAST CANCER",
    "overallStatus": "COMPLETED",
    "conditions": "Advanced, Androgen Receptor Positive Triple Negative Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2",
    "allocation": "NA",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 118,
    "primaryOutcomeMeasure": "Percentage of Participants With Clinical Benefit at Week 16: Evaluable Population",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Women at least 18 years of age;\n* Advanced AR+ TNBC;\n* Availability of a representative tumor specimen:\n* Either measurable disease or bone only nonmeasurable disease;\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.\n\nExclusion Criteria:\n\n* Any severe concurrent disease, infection, or comorbid condition;\n* Any condition or reason that interferes with the patient's ability to participate in the trial, that may cause undue risk, or complicates the interpretation of safety data;\n* Current or previously treated brain metastasis or active leptomeningeal disease;\n* Current hormone replacement therapy;\n* Local palliative radiation therapy within 7 days before day 1;\n* History of another invasive cancer within 5 years of day 1;\n* Absolute neutrophil count \\< 1500/\u00b5L, platelet count \\< 75,000/\u00b5L, or hemoglobin \\< 9 g/dL (5.6 mmol/L) at the screening visit;\n* Creatinine \\> 1.5 times upper limit of normal (ULN) at the screening visit;\n* History of seizure or any condition that may predispose to seizure;\n* Clinically significant cardiovascular disease;\n* Active gastrointestinal disorder affecting absorption;\n* Major surgery within 4 weeks before day 1;\n* Treatment with any commercially available anticancer agent within 14 days before day 1;\n* Treatment with any investigational agent within 2 weeks before day 1;\n* Treatment with any of the following medications within 2 weeks before day 1: Estrogens, including hormone replacement therapy; Androgens (testosterone, dihydroepiandrosterone, etc);Systemic radionuclides (eg, samarium or strontium);Vaccine therapy;\n* Hypoglycemic episode requiring medical intervention while on insulin treatment within 12 months before day 1;\n* Hypersensitivity reaction to the active pharmaceutical ingredient or any of the capsule components, including Labrasol, butylated hydroxyanisole, and butylated hydroxytoluene.",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}